INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known	
Application Number	09/525,797	
Filing Date	03/15/2000	
First Named Inventor	Athanasius A. Anagnostou	
Group Art Unit	1642	
Examiner Name	Susan Ungar	

Sheet	G1	of	G1	Attorney Docket Number	5218-39B

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Urushizaki, I. Domain of Chemotherapy, 10(6):1031-1037 (1994)	Partial
	2.	Anagnostou et al., "Erthropoietin has a mitogenic and positive chemotactic effect on endothelial cells", Proc. Natl. Acad. Sci. USA, 87(15):5978-5982 (1990)	
	3.	Fujioka et al., "Effects of recombinant erythropoietin on kidney cancer cell growth and tumor angiogenesis", Autologous Blood Tansfusion, 8(1):46-50 (1995)	Partial
	4.	Nagai, T., "Effects of rHuEPO on cellular proliferation and endothelin-1 production in cultured endothelial cells", J. of Japanese Soc. Of Nephrology, 36(3):194-200 (1994)	Partial
	5.	Japanese Office Action corresponding to Japanese Patent Application No. 513794/1998 mailed August 28, 2007.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.